Arrowhead Surges Into the S&P MidCap 400 as REDEMPLO Gains Fuel Turnaround

Arrowhead Pharmaceuticals has achieved a dual milestone: its inclusion in the S&P MidCap 400 and a clear turnaround in profitability, backed by the commercial rollout of its new therapy REDEMPLO and stronger quarterly results. With early uptake of REDEMPLO and a healthier bottom line, investors are weighing how quickly the company can scale its market presence. Street projections remain constructive, as evidenced by a broad set of favorable price targets.

Key Financials this quarter
- Quarterly revenue: 264.03 million USD (significantly above year-ago levels)
- Net income: 30.81 million USD (return to profitability)
- Average price target: 81.67 USD
- Index transition: effective February 9, moving to the S&P MidCap 400

Index transition and ownership structure
The move from the S&P SmallCap 600 to the S&P MidCap 400 marks a liquidity and visibility upgrade for Arrowhead. Such reclassifications often prompt index funds to adjust holdings, influencing ownership dynamics. Presently, institutional investors own 62.6% of the company’s shares. Despite this solid base, insiders sold about 33.6 million USD of stock in the last three months.

Turnaround drivers and product launch
The company’s results for the year ending December 31 show a clear swing into profit, with a net income of 30.81 million USD after a loss in the prior year. One of the key contributors has been milestone payments from partnerships with large pharma players, including Novartis and Sarepta Therapeutics. Parallel to the financial improvement, the commercial rollout of REDEMPLO (plozasiran) has begun to take hold. Since regulatory approval in November 2025, more than 100 prescriptions had been issued in the first ten weeks. Notably, about 70% of these prescriptions originated from cardiologists and endocrinologists, signaling targeted uptake within the relevant specialist community. Arrowhead sits on a cash reserve of 917 million USD, underscoring a solid financial footing to support ongoing market expansion.

Analyst sentiment and targets
The outlook among market commentators remains favorable. Of eleven analysts covering the stock, seven rate it Buy or Strong Buy, while four assign a Hold. There are no Sell recommendations at this time. Price targets vary widely: the most conservative sits near 35 USD, while optimistic assessments go up to 110 USD. The collective consensus target stands at 81.67 USD.

Outlook
Looking ahead, the focus shifts to the revenue trajectory for REDEMPLO and the continued stabilization of profitability. Arrowhead’s substantial cash pile provides flexibility to pursue its commercialization plan without an immediate need to raise additional capital, supporting a potentially rapid expansion of its commercial footprint if demand holds.